Gliquidone (AR-DF 26) is a potent, second-generation sulfonylurea with antihyperglycemic activity, exhibiting greater binding affinity to SUR1 and increased potency compared to first-generation compounds. Additionally, this agent exerts peroxisome proliferator-activated receptor (PPAR) gamma agonistic activity.

K+ channel:27.2 nM

Intraventricular administration of 0.06–16 μg Gliquidone to each mouse counteracts the antinociceptive effects of tramadol, morphine, and methadone. A dose of 6 μg Gliquidone intraventricularly administered to each mouse inhibits the antinociceptive responses induced by subcutaneous injections of 0.125 mg/kg clonidine and 0.30 mg/kg chlorthalidone; however, a 3 μg dose is ineffective. In male Swiss albino mice, intraventricular injections of 0.1–1.0 μg Gliquidone dose-dependently suppress the antinociceptive effects of amitriptyline and chlorphenamine. In diabetic rats, a 10 mg/kg dose of Gliquidone significantly reduces blood pressure, diminishes non-enzymatic glycation, lowers total protein levels in the lens, and notably increases glutathione levels in the lens.